JPMorgan lowered the firm’s price target on Ascendis Pharma (ASND) to $174 from $180 and keeps an Overweight rating on the shares after speaking with CEO Jan Mikkelsen. The firm continues to like the Ascendis story heading into the U.S. Yorvipath launch in hypoparathyroidism and thinks investors will want to own the stock for the launch. However, it trimmed its Q4 and Q4 Skytrofa revenue estimates and now models total 2024 Skytrofa revenue of EUR 215M. The analyst thinks the stock will work post the Q3 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASND:
- 3 Best Stocks to Buy Now, 10/21/2024, According to Top Analysts
- Ascendis Pharma price target raised to $160 from $157 at TD Cowen
- Ascendis Pharma participates in a conference call with JPMorgan
- Nike upgraded, PayPal downgraded: Wall Street’s top analyst calls
- Ascendis Pharma Updates Corporate Charter and Capital Structure
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
